New therapeutic targets such as the GSK3β signaling pathway (231), NLRP3 inflammatory vesicles (232), PI3K/Akt and JAK/STAT pathways (233), endothelin receptor (234), and DPP-4 (235) are involved in the pathological progression of DN, and there is still an urgent need to identify and validate new drug targets and candidates for better DN therapy. This evidence concerns the gene AKT1 and liver dysplastic nodule.